Neumora Therapeutics Plummets After Drug Trial Failure
Neumora Therapeutics shares hit rock bottom after its depression drug failed in a Phase 3 trial. Discover the impact on the company's stock and future prospects.
Topic
Neumora Therapeutics
A collection of 5 issues
Neumora Shares Dive as Depression Drug Fails Phase 3 Trial
Neumora Therapeutics shares nosedived after its promising depression drug failed in a crucial Phase 3 trial, impacting investor confidence. Learn more about the implications.
Neumora Therapeutics Shares Plummet 80% After Drug Trial Failure
Neumora Therapeutics stock plummets 80% to $2.05 after pivotal Phase 3 trial of their depression drug fails, impacting investor confidence.
Neumora Therapeutics Faces 80% Stock Plunge After Drug Trial Setback
Neumora Therapeutics' navacaprant fails Phase 3 trial endpoints, causing an 80% stock value drop. Discover the impact of this significant biotech setback.
Neumora Shares Plummet After Depression Drug Trial Fails
Neumora Therapeutics Inc. faces a setback as its depression drug, navacaprant, fails in a critical final-stage study, causing a sharp decline in shares.